Abstracts Archive - Page 401 of 2607 - ACR Meeting Abstracts

Abstract Number: 1165 • ACR Convergence 2023
Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Jenice Cheah¹, Sangmee Bae², Tiffany De Leon², Yuna Lee¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Rheumatology, Los Angeles, CA, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
Abstract Number: 1309 • ACR Convergence 2023
Refractory RA Patients for Targeted Therapies in Real Life
Elena Grau Garcia¹, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez³, Carmen Riesco Barcena¹, Alba Maria Torrat Noves¹, Daniel Ramos Castro¹, Anderson Victor Huaylla Quispe¹, Iago Alcantara Alvarez¹, Belen Villanueva Mañez¹, Ernesto Tovar Sugrañes¹, Elvira Vicens Bernabeu¹, Hikmat Charia¹, Marta De la Rubia Navarro², Luis Gonzalez Puig¹, Jose Ivorra Cortes¹, Samuel Leal Rodriguez¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Ines Canovas Olmos¹, Carmen Najera Herranz¹ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valéncia, Spain, ³Rheumatology Department. HUP La Fe, Sagunto, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Despite the increasing number of available targeted therapies (TT) in rheumatoid arthritis (RA), a proportion of RA patients fail to respond to their first…
Abstract Number: 1357 • ACR Convergence 2023
Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review
Erinn Coe¹, Emily Petrinec¹ and Omer Pamuk², ¹Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ²Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in women of childbearing age and female sex hormones are known to…
Abstract Number: 1361 • ACR Convergence 2023
Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy…
Abstract Number: 1360 • ACR Convergence 2023
Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort
Yvette Meissner¹, Bernhard Eickhoff¹, Cornelia Glaser², Joerg Henes³, Jutta Richter⁴, Susanna Spaethling-Mestekemper⁵, Christof Specker⁶, Rebecca Fischer-Betz⁴ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology University Medical Center Freiburg, Freiburg, Germany, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Düsseldorf, Germany, ⁵Rheumapraxis Muenchen, Muenchen, Germany, ⁶Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Pregnancies in women with chronic diseases are often accompanied by concerns about potential complications [1]. This analysis explored medication-related concerns among women with inflammatory…
Abstract Number: 1356 • ACR Convergence 2023
Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Amaya Smole¹, Lucy Masto¹, Caroline Siegel¹, Sarah Lieber², Sanjana Adurty³, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl², Michael Lockshin², Lisa Sammaritano² and Medha Barbhaiya², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY
Background/Purpose: Women with systemic rheumatic diseases (SRDs), particularly those with SLE, may be more vulnerable to HPV infection and HPV-related cervical cancer. However, HPV testing…
Abstract Number: 1350 • ACR Convergence 2023
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Noah Forrest¹, Joshua Waytz², April Barnado³, Megan Clowse⁴, Theresa Walunas¹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern Medicine, Chicago, IL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Duke University, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL
Background/Purpose: SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in…
Abstract Number: 1343 • ACR Convergence 2023
Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years
Xavier Mariette¹, Sven Borchmann², Sandrine Aspeslagh³, Jaime Calvo- Alén⁴, Richard Moriggl⁵, Zoltan Szekanecz⁶, Francesco De Leonardis⁷, Nadia Verbruggen⁸, Paul Van Hoek⁹, Marc Schmalzing¹⁰, Andreas Stallmach¹¹, Christina Charles-Schoeman¹², Vijay Rajendran¹³, Christine Rudolph⁹, Chris Watson¹⁴, Yoshiya Tanaka¹⁵ and Ernest Choy¹⁶, ¹Université Paris-Saclay, Le Kremlin-Bicêtre, France, ²Department of Internal Medicine, University of Cologne, Cologne, Germany, ³Department of Medical Oncology, UZ Brussel, Brussels, Belgium, ⁴Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁵Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria, ⁶Division of Rheumatology, University of Debrecen, Debrecen, Hungary, ⁷Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁸Biostatistics, Galapagos NV, Mechelen, Belgium, ⁹Medical Safety, Galapagos NV, Mechelen, Belgium, ¹⁰University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ¹¹Department of Internal Medicine, Jena University Hospital, Jena, Germany, ¹²UCLA Medical Center, Santa Monica, CA, ¹³Clinical Research, Galapagos NV, Mechelen, Belgium, ¹⁴Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁶Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor for the treatment of RA. Data from the ORAL Surveillance post-marketing study (NCT02092467) suggest…
Abstract Number: 1273 • ACR Convergence 2023
Long-term Follow-up of Treated-to-target RA and UA: Results of the BeSt and IMPROVED Studies
Sascha Heckert¹, Johanna Maria Maassen¹, Isabell Nevins², F. Fodili³, Margreet Steup-Beekman⁴, Thomas Huizinga¹, Sytske Anne Bergstra¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Amsterdam, Netherlands, ³Stichting ReumaZorg ZWN, Roosendaal, Netherlands, ⁴Leiden University Medical Center, Den Haag, Netherlands
Background/Purpose: In 2 trials with an original follow-up of 5-10 years, patients with early arthritis were treated to target, resulting in low disease activity or…
Abstract Number: 1175 • ACR Convergence 2023
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Yusra Hasan¹, Katharine Ching Chung², Dana Ascherman³, Siamak Moghadam-Kia⁴, Chester V. Oddis³ and Rohit Aggarwal³, ¹CHI Health Creighton University Medical Center, Omaha, NE, ²University of Pittsburgh Medical Center, Mckeesport, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…
Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 1363 • ACR Convergence 2023
Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills
Background/Purpose: Women develop RA 3 times more often than men, and several risk factors for RA are female specific. Prior studies demonstrate an association between…
Abstract Number: 1365 • ACR Convergence 2023
Extraglandular Involvement and Autoantibody Status as Risk Factors for Cardiovascular Disease in Primary Sjogren’s Syndrome (pSS): A 20 Year-follow up Study
Cristiana Sieiro Santos¹, Rúben Rego Salgueiro², Clara Moriano Morales³, Carolina Álvarez Castro³ and Elvira Díez Álvarez³, ¹Complejo Asistencial Universitario de León, León, Spain, ²ULS Guarda, Guarda, Portugal, ³CAULE, León, Spain
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disorder characterized by chronic multisystem inflammation with shared pathophysiology with SLE and RA. Cardiovascular events have emerged…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…
Abstract Number: 1374 • ACR Convergence 2023
Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Marco Sprecher¹, Florine Weber², Kastriot Kastrati³, Helmut Prosch⁴, Natasha Moe⁵, Emily Langballe⁶, Cosimo Bruni⁷, Oyvind Molberg⁸, Phuong Phuong Diep⁹, Christian Clarenbach¹⁰, Paul Studenic¹¹, Helena Andersson⁸, Oyvind Midtvedt¹², Torhild Garen⁸, Karoline Lerang¹³, Thomas Frauenfelder¹⁴, Helga Radner¹⁵, Oliver Distler⁷ and Anna Maria Hoffmann-Vold¹⁶, ¹Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ⁴Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁵Dept of Radiology, University Hospital Oslo, Oslo, Norway, ⁶Universitetet i Oslo, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹¹Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁴Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁵Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁶Oslo University Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].